Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 58Active not recruiting 18Recruiting 14Terminated 4Unknown 3Not yet recruiting 3Withdrawn 2Approved for marketing 1

Sponsor Class

OTHER 15INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × pertuzumab × Clear all
NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Biocon Limited

Phase 3 Terminated
55 enrolled
Breast

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Bolt Biotherapeutics, Inc.

Phase 2 Terminated
11 enrolled 13 charts
Breast

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

US Oncology Research

Phase 2 Terminated
33 enrolled
Breast

Breast Neoplasms

NCT02480010 2015-09-18

A Study of Pertuzumab in Participants With Prostate Cancer

Hoffmann-La Roche

Phase 2 Terminated
68 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡